Activation of G protein‐coupled receptor 39 alleviates neuropathic pain and chronic inflammation

Abstract Neuropathic pain (NP) is mainly caused by lesions or diseases of the somatosensory nervous system and triggers severe physical burdens to patients. It is claimed that activated microglia‐mediated neuroinflammation participates in the development of NP, which is regulated by p38 mitogen‐activated protein kinase (MAPK)/nuclear factor‐κappa B (NF‐κB) p65 signaling. G protein‐coupled receptor 39 (GPR39) is a trans‐membrane protein involved in the activation of cellular transduction pathways, and TC‐G 1008, a GPR39 agonist, is believed to have inhibitory effects on neuroinflammation. Our study will explore the possible alleviatory function of TC‐G 1008 on NP in a rat model. GPR39 was found markedly downregulated in the spinal dorsal horn of chronic constriction injury (CCI)‐stimulated rats. Rats were treated with CCI, followed by intranasal administration with 7.5 and 15 mg/kg TC‐G 1008 at 1, 25, 49, and 73 h postmodeling, respectively. Drastically lowered values of paw withdrawal threshold and paw withdrawal latency, upregulated ionized calcium‐binding adapter molecule 1, increased release of inflammatory cytokines, elevated spinal malondialdehyde levels, and reduced spinal glutathione peroxidase levels were observed in CCI‐stimulated rats, all of which were markedly alleviated and rescued by TC‐G 1008. Furthermore, the levels of p‐p38/p38 and p‑NF‑κB p65 were found signally repressed in the spinal dorsal horn of CCI‐stimulated rats, which was notably reversed by TC‐G 1008. Collectively, TC‐G 1008 markedly alleviated NP and neuroinflammation in CCI‐treated rats. Our findings provide an attractive future direction for the treatment of NP.